Skip to main content
Clinical Trials/ACTRN12616000741482
ACTRN12616000741482
Completed
未知

A randomised placebo controlled clinical trial on the efficacy of Caralluma supplement for anxiety and stress in healthy adults over eight weeks

RDC Global0 sites117 target enrollmentJune 6, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
Anxiety
Sponsor
RDC Global
Enrollment
117
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 6, 2016
End Date
May 12, 2017
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
RDC Global

Eligibility Criteria

Inclusion Criteria

  • Participants will be included for assessment if they self\-report mild\-moderate anxiety (BAI \>9\<30\), are not diagnosed with depression or a mood disorder, are otherwise healthy, and have given written informed consent.

Exclusion Criteria

  • Participants will be excluded if they:
  • have a known hypersensitivity to herbal drugs, or nutritional supplements;
  • have been diagnosed with hypertension and are receiving medication;
  • have a medical condition which, in the opinion of the investigator, makes them unsuitable or deemed unhealthy (including a BMI \> 30\);
  • have currently or have a history of chronic alcohol and/or drug abuse;
  • have participated in any other clinical trial during last 30 days;
  • are currently participating in another clinical trial;
  • have been diagnosed with a mood disorder;
  • have minimal or severe anxiety on the Beck Anxiety Inventory (\<10, or \> 29\);
  • suffered severe PMS with mood or pain that would change during the study;

Outcomes

Primary Outcomes

Not specified

Similar Trials